The global distributed control systems market was valued at US$ 17.99 Bn in 2020 and expected to register strong growth, expanding at a CAGR of 4.3% during the forecast period from 2025 to 2033.
The pharmaceutical intermediates market is set to reach from US$ 29,080.8 Mn in 2021 to US$ 41,317.4 Mn by 2033 at a compound annual growth rate (CAGR) of 4.0% during the forecast period from 2025 to 2033. Significant rise in drug formulation and research activities and supportive regulatory environment provided by global healthcare agencies will consolidate the pharmaceutical intermediates market during the forecast period.
Polymyositis treatment market projected to grow at a CAGR of 5.9% during the forecast period from 2025 to 2033. Polymyositis is rare connective tissue disease that causes muscle inflammation leading to muscle weakness. According to prevalence studies, globally the incidence of polymyositis is around 1 to 5 per 100,000 individuals and the prevalence is approximately 5 to 22 per 100,000 individuals. Thus, high awareness related to polymyositis diagnosis & treatment, strong drug pipeline, and rising geriatric population expected to assist the growth of polymyositis treatment market in the near future.
Paget’s disease treatment market is projected to grow at a CAGR of 3.4% during the forecast period from 2025 to 2033. Paget’s disease of bone affects the way that bone is renewed & repaired, during this process an uncontrolled level of bone generation occurs that results into an abnormal bone formation. The affected bone is weaker than normal and leads to a bend or deformity making that bone fragile.
Text analytics is an emerging technology in the field of big data analytics targeted to handle unstructured text data. Due to data deluge, there is a huge demand for text analytics from various end user industries, such as BFSI, Healthcare FMCG’s, Telecom, and so on, which is a major driver for the text analytics market.
The paroxysmal nocturnal hemoglobinuria (PNH) is currently valued at US$ 3,163.2 Mn in 2021 and is set to reach US$ 8,380.2 Mn by 2033 projecting stunning growth at a compounded annual growth rate (CAGR) of 11.7% during the forecast period from 2025 to 2033. PNH is a rare disease wherein red blood cells are reported to burst prematurely. It has a global incidence rate of 1.3 cases per million people. The high treatment cost and mortality rate associated with stem cell transplant procedures has increased the popularity of monoclonal antibodies as the most effective treatment molecule for the treatment of PNH.
The neurotrophic keratitis market is set to highlight rapid growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2025 to 2033. Neurotrophic keratitis is an orphan disease which is primarily caused due to the damage of the fifth cranial nerve from the trigeminal nucleus to the nerve endings preset in the eye corneal region. Traditional therapies are employed to suppress the clinical manifestation occurring in different stages of the disease.
The Lambert-Eaton Myasthenic Syndrome (LEMS) market is keen to represent linear growth at a compounded annual growth rate (CAGR) of 6.7% during the forecast period from 2025 to 2033. LEMS is a rare autoimmune disorder which is manifested by the clinical triad which comprises of reduced tendon reflexes, autonomic symptoms and proximal muscle weakness. Most of the patients suffering with LEMS go undiagnosed at an early age due to its overlapping symptoms similar to small cell lung cancer (SCLC).
Alpha thalassemia treatment market accounted for a market value of US$ 643.4 Mn in 2021 and projected to grow at a CAGR of 7.1% during the forecast period from 2025 to 2033. Alpha thalassemia is a congenital autosomal recessive disorder caused due to absence or reduction in alpha globin peptides due to a deletion or mutation of the alpha globin genes.
The global freezing of gait treatment market is growing effectually, expected to grow at a CAGR of 7.2%. Globally, increasing prevalence of Parkinson's disease has significantly increased the revenue of oral dopaminergic medications. FDA approval for new drugs, and promising pipeline products in the equipment and devices segment in the Parkinson's disease industry are driving the overall growth freezing of gait treatment market globally.
The drugs by therapeutic area include therapy for oncology, cardiovascular, central nervous system, infectious diseases, respiratory, and others. The therapeutic area represents the specific area of medicine where the drug is intended to be used, based on its mechanism of action and intended clinical use. One of the primary drivers of the drugs by therapeutic area market is the increasing prevalence of diseases worldwide. Chronic diseases such as cancer, cardiovascular diseases, and neurological disorders are a significant burden on healthcare systems globally. There is an urgent need for new and effective therapies to treat these diseases, which has led to the growth of the drugs in the therapeutic area market.
The revenues generated by the drugs in the therapeutic area market have been consistently high over the years. The global pharmaceutical market is expected to reach USD 1.5 trillion by 2023, with oncology being the leading therapeutic area. The increasing demand for new therapies, coupled with advancements in technology and an increasing focus on personalized medicine, is expected to drive the growth of the market in the coming years. One of the emerging trends in the drugs by therapeutic area market is the increasing use of precision medicine. Precision medicine involves tailoring medical treatments to individual patients based on their unique genetic and molecular profiles. The development of precision medicine requires the use of advanced diagnostic tools and drug discovery technologies, which have contributed to the growth of drugs in the therapeutic area market.
Another trend in the drugs by therapeutic area market is the increasing focus on biologics. Biologics are drugs that are produced from living cells and are used to treat a wide range of diseases, including cancer and autoimmune disorders. Biologics are more complex than traditional small-molecule drugs, and their development requires specialized manufacturing processes and clinical trial design. The increasing demand for biologics has contributed to the growth of the drugs by therapeutic area market. The increasing focus on rare diseases is also driving the growth of the drugs by therapeutic area market. Rare diseases are defined as diseases that affect fewer than 200,000 people in the United States. Although each rare disease affects a small number of people, there are over 7,000 rare diseases, which together affect millions of people worldwide. There is an urgent need for new therapies to treat rare diseases, which has led to the growth of drugs in the therapeutic area market.
The increasing use of combination therapies is driving the growth of the drugs by therapeutic area market. Combination therapies involve the use of two or more drugs to treat a disease. Combination therapies can improve patient outcomes by targeting multiple pathways involved in the disease process. The development of combination therapies requires the use of advanced drug discovery technologies and clinical trial design, which has contributed to the growth of the drugs by therapeutic area market. The increasing prevalence of diseases worldwide, advancements in technology, and the emerging trends in precision medicine, biologics, rare diseases, and combination therapies are expected to drive the growth of the drugs by therapeutic area market.
